THC, CP-55,940 and WIN Cross-Tolerance Varied Quantitatively Across Mouse Tests
A 1994 mouse study found cross-tolerance among THC and two structurally different synthetic cannabinoid agonists, but the magnitude varied by pretreatment and test. Shared actions did not establish interchangeable dose-response behavior.
The comparison retained exposure direction
Mice received repeated THC or CP-55,940 before challenges with the tested cannabinoids. Those histories are different experimental conditions. Cross-tolerance observed after one pretreatment does not establish an identical shift after reversing the sequence.
The measured functions had different shifts
The researchers assessed movement, temperature, antinociception and catalepsy. Repeated CP-55,940 produced particularly large shifts on some endpoints, while the THC-associated shifts differed in magnitude. One generalized tolerance multiplier would therefore conceal the actual pattern.
Overlap does not prove one complete mechanism
The authors interpreted the findings as evidence of some actions in common while retaining possible differences. A shared receptor interaction or a rightward response-curve shift cannot by itself establish that every action is identical. The animal assay remains distinct from a patient response.
Interpreting the evidence
For a cross-tolerance comparison, retain the challenge compound, pretreatment, endpoint and measured shift. This experiment does not provide an equivalence table for consumer cannabinoids or justify assuming that tolerance protects against a different agonist's adverse effects.
Related reading: interpreting cannabis tolerance claims.
Research reference
Fan F; Compton DR; Ward S; Melvin L; Martin BR (1994). Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. The Journal of pharmacology and experimental therapeutics. PubMed research record.
This analysis draws on the supplied study abstract.
